ENGLEWOOD, Colo., July 10, 2025 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) is pleased to announce that Barclays Capital Inc. has purchased $40 million of newly issued non-recourse tax-exempt private activity bonds (the “2025 Bonds”) issued by the Iowa Finance Authority for the benefit of Gevo’s wholly owned subsidiary, Gevo NW Iowa RNG, LLC (“Gevo RNG”). The bond proceeds were used to refinance $40 million of the previously issued Iowa Finance Authority Solid Waste Facility Revenue Bonds (Gevo NW Iowa RNG, LLC Renewable Natural Gas Project), Series 2021 (Green Bonds) (the “Previous Bonds”), which were issued in the aggregate principal amount of $68.2 million and secured by an irrevocable direct pay letter of credit. This partial refinancing of the Previous Bonds enabled Gevo to release $40 million of restricted cash that was securing the letter of credit and increase its balance sheet liquidity by approximately $30 million after paying transaction costs and funding reserves associated with the 2025 Bonds.
In this 2025 product availability update, BRĒZ shares how its legal microdosed THC drinks are redefining the fast-growing functional beverage space—offering adults new access to non-alcoholic, hemp-derived cannabis tonics aligned with the search for the best THC drink alternatives.
In this 2025 product availability update, BRĒZ shares how its legal microdosed THC drinks are redefining the fast-growing functional beverage space—offering adults new access to non-alcoholic, hemp-derived cannabis tonics aligned with the search for the best THC drink alternatives.
ENGLEWOOD, Colo., July 08, 2025 (GLOBE NEWSWIRE) -- Gevo, Inc. (NASDAQ: GEVO) announced today that Leke Agiri, Gevo’s Chief Financial Officer, and Eric Frey, Gevo’s Vice President of Finance and Strategy, will participate in a virtual fireside chat on Wednesday, July 9, 2025 at 10:00am ET.
OCI Global ("OCI") announces successful completion of the sale of 100% of its equity interests in its Global Methanol Business ("OCI Methanol") to Methanex...
Differences in manufacturing processes impact the tolerability of intravenous immune globulin (IVIG) products GC Biopharma's manufacturing process reduces FXIa to undetectable levels – a critical...